Drug intelligence / Profile preview

PBK_L1704

Development stage: Phase 3
Lead developer: Pharmbio Korea
Modality: Small Molecules

Overview

PBK_L1704 is a novel analgesic drug developed by Pharmbio Korea for the treatment of moderate to severe acute pain, particularly after bunionectomy. It is classified as a chemical drug and considered a new molecular entity. The precise mechanism of action has not been disclosed or defined in public sources, and it is currently under late-stage clinical development (Phase 3) in South Korea for acute pain indications. There are no approved indications or known adverse events reported as of the latest updates[1][2][7].

Beyond the preview

Go deeper on PBK_L1704.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBK_L1704.

Explore the full profile